Summary The aim of this study was to examine pulmonary function after acute tymphoblastic leukaemia in childhood and identify risk factors for reduced pulmonary function. We studied a population-based cohort of 94 survivors of acute lymphoblastic leukaemia in childhood who were in first remission after treatment withut spinal irradiation or bone marrow transplantation. Pulmonary function test results were compared with reference values for our laboratory, based on 348 healthy subjects who had never smoked from a local population study. A median of 8 years after cessation of therapy (range 1-18 years) the participants had a slight, subclinical, restrictive ventilatory insufficiency and reduced transfer factor and transfer coefficient. The changes in lung function were related to younger age at treatment and to more doseintensive treatment protocols that specified rnore use of cranial irradiation and higher cumulative doses of anthracyclines, cytosine arabinoside and intravenous cyclophosphamide than previous protocols. We conclude that, 8 years after treatment without bone marrow transplantation or spinal irradiation, survivors of childhood acute lymphoblastic leukaemia in first remission were without pulmonary symptoms but had signs of slight restrictive pulmonary disease including reduced transfer factor. The increased dose intensity of many recent protocols for childhood acute tymphoblastic leukaemia may lead to increased late pulmonary toxicity.
Dunn the last decades the survival rate after childhood acute lymphoblastic leukaemia (ALL) has been considerably improved (Pui. 1995) . Consequently. the frequency and severity of late effects in survivors of childhood ALL have gained importance.
A few reports have been published on the lung function after childhood leukaemia (Miller et al. 1986 : Shaw et al. 1989 : Jenney et al. 1995 : Turner-Gomes et al. 1996 . Two groups of 15 and 31 childhood leukaemia survivors had a slight restrictive pulmonary disease 3-7 years after the end of therapy (Miller et al. 1986 : Shaw et al. 1989 ). In contrast. 19 ALL survivors in first remission had normal lung volumes and transfer factor 4 years after the end of therapy (Tumer-Gomes et al. 1996) . None of these studies identified any risk factors for reduced pulmonary function.
In the largest study to date. 70 childhood leukaemia survivors. examined 4 years after the end of therapy. had lower lung volumes and transfer factor than 146 matched control subjects (Jenney et al. 1995) . Chest infections. cyclophosphamide and craniospinal irradiation were risk factors for reduced lung volumes. whereas chest infections. doxorubicin. craniospinal irradiation and bone marrow transplantation were risk factors for reduced transfer factor. Chest infections were defined as the number of lower respiratory tract infections requiring hospitalization during or subsequent to the treatment for leukaemia. irrespective of whether or not an underlying cause was identified (Jenney et al, 1995) .
Most of the previous studies had several limitations. such as few participants. many patients lost to follow-up, short follow-up. lack of control groups. or many different diagnoses. stages of disease and treatments included. The two largest studies (Shaw et al. 1989 : Jenney et al. 1995 both included patients treated with spinal irradiation and patients treated with total body irradiation and bone marrow transplantation. which are treatments known to cause reduced pulmonary function (Jakacki et al. 1995 : Nysom et al. 1996 . Thus. the lung function of the majority of childhood ALL survivors -patients in first remission treated without bone marrow transplantation or spinal irradiation -is not well described.
We studied the pulmonary function of 94 survivors of childhood ALL who were in first remission several years after diagnosis and had never been treated with bone marrow transplantation or spinal irradiation.
PATIENTS AND METHODS Patients
From the population-based Danish Cancer Registry (de Nully Brown et al. 1989 ) 304 cases of ALL were identified. These patients were at most 14 years old and diagnosed between 1970 and 1990 (inclusive) while residing in east Denmark. On 1 January 1993, 11 patients were still on therapy and 127 had died. Only four patients who had emigrated were lost to follow-up. Of 162 eligible patients. 128 (79%) gave their informed consent to participate in the present study. Thirty-two patients declined to participate for personal reasons, one was pregnant. and one had a relapse before being studied. Two participants could not perform the pulmonary function tests because of young age. To study the pulmonary function after standard ALL therapy. we excluded 24 patients treated for a relapse. one treated for a second malignancy and seven other patients treated with bone marrow transplantation. mediastinal irradiation or carmustine. This leaves 94 participants off therapy in first remission of ALL for the present analysis.
The median age of the participants was 3.9 years at diagnosis (range 0.5-14.8 years). 6.9 years at completion of therapy (3.5-19.7 years) and 16.2 years at time of the study (5.3-34.2 years). The median length of follow-up was 10.6 years from diagnosis (3.4-23.4 years) and 7.6 years from completion of therapy (1.2-18.3 years).
The participants had received chemotherapy and cranial irradiation as described in Table 1 . The dose of cranial irradiation was 15-18 Gy (n = 23) or 24 Gy (n = 16). No participants received other types of irradiation.
The height of the participants at time of the study ranged from 119 to 179 cm in female subjects and from 110 to 185 cm in male subjects. The average height did not differ significantly from national reference data (mean standardized residual -0.1. 95% confidence interval -0.3 to 0.1. range -2.1 to 3.0) (Andersen et al. 1982) . Participants who had received cranial irradiation were significantly shorter than the other participants (estimated difference between means 0.8 standardized residual. 95% confidence interval 0.4-1.2). but their sitting height to standing height ratio did not differ significantly from local reference data (Holm. 1996) .
At the time of the study 18 participants smoked, four had previously smoked. whereas 72 had never smoked. The four who had previously smoked were all considered as smoking subjects as they had consumed the same median amount of cigarettes as the 18 current smoking subjects and as they had stopped smoking only 2-17 months before being studied. This gave a group of 22 smoking subjects in all (seven men. P = 0.05 for more women who smoked). who had consumed a median of 1.5 pack-years of cigarettes (1 pack-year is 20 cigarettes a day for 1 year: range 0.1-10.5) over a median period of 3 years ( 1-13 years).
Pulmonary function testing
All pulmonary function tests were performed in the same laboratory in accordance with the European recommendations (Quanjer and Tammeling. 1983) . The forced expiratory volume in 1 second (FEVd) Pulmonary function after childhood ALL 23 Rosenthal et al. 1993; Quanjer et al. 1995 : Stam et al. 1996 to fit 348 healthy 13-to 24-year-old Caucasian subjects who had never smoked from a local population study (Nysom et al. 1997 (Altman, 1991) . Probabilities below 0.05 were considered statistically significant and data were analysed using the SAS computer software package (SAS Institute. Cary. NC. USA).
Ethics
All participants and the parents of the children younger than 18 gave their written informed consent. The study was in accordance with the Helsinki II declaration and was approved by the local medical ethics committee of Copenhagen. Denmark (approval no. KF V92-097).
RESULTS Participants
At the time of the study one participant received captopnrl for arterial hypertension. and one used beclomethasone inhalations for asthma Ten participants had pulmonary symptoms: one complained of dyspnoea. two complained of cough at night. five complained of cough on exertion. one complained of cough at night and on exertion, whereas one complained of dyspnoea and cough at night Eighty-four participants had no pulmonarv symptoms. Fourteen participants (including five smoking subjects) considered their physical work capacity better than that of other people of their own age, 63 (14 smoking subjects) considered it equal to that of other people of their own age. 14 (three smoking subjects) considered it a bit inferior, and three (non-smoking subjects) much inferior. Five participants had haemoglobin concentrations 0.2-1.1 dl-' below the lower limits of normal of our laboratory. All others had values evenly distributed within the normal range of our laboratory (5-7 years: 11.9-14.8, 7-13 years: 12.1-15.6. female subjects > 13 years: 11.3-16.1. male subjects >13 years: 12.9-17.7 gdl-). (Table 2) .
Two flow-volume curves were classified as obstructive, and one was also restrictive. None of these curves were from smoking subjects or patients with short expirations. Eighteen other flow-volume curves appeared restrictive, including the curves of seven patients (one smoking subject) with a low TLC.
Transfer factor and transfer coefficient
The mean transfer factor and transfer coefficient standardized residuals were significantly reduced both in non-smoking subjects and in smoking subjects ( Table 2 ). Table 3 . Age at followup was significantly correlated with TLC and also with the treatment related variables considered (non-parametric correlation coefficient -0.37 to -0.59, P < 0.0002). Neither age at follow-up, length of follow-up, nor smoking improved any of the multiple regression models significantly.
When we applied the multiple regression models in Table 3 to the 52 participants who were within the height and age range of the local control group, the estimated regression coefficients were all within the confidence intervals given in Patients trated according to the intermediate or high-risk protocols accounted for 7 (no smoking subject) of the 12 patients with an abnormally low transfer factor, and for five (two smoking subjects) of the ten patients with a low transfer coefficient. Four of the patients with a low transfer factor also had a low TLC. The transfer factor and TLC were strongly correlated (parametnc correlation coefficient 0.56, P < 0.0001), and a model for the transfer factor was ftuther improved by adding the smoking state [regression coefficients +0.57 (95% confidence interval 0.40-0.75, TLC) and -0.46 (-0.85 to -0.06, smoker) ]. None of the other thireen variables considered for predicting the TLC (Table 3) significantly improved this model when they were entered one at a time (P = 0.08-0.84).
At the integrated evaluation of pulmonary function, the frequency of pulmonary abnormalities was significantly higher among patients treated according to the intmediate or high-risk protocols (23 of 45) than among the remaining patients (14 of 49, P = 0.04).
DISCUSSION
Eight years after cessation of treatment for ALL, several of our participants had a subclinical, restrictive ventilatory insufficiency based on TLC and a high frequency of restrictive flow-volume curve pattems. The changes in lung function were related to younger age at treatment and to the dose-intensive treatnent protocols of the 1980s that specified higher cumulative doses of anthracyclines, intravenous cyclophosphamide and cytosine arabinoside, and more frequent use of cranial irradiation, than previous protocols. The changes were slight: according to the European reference values (Quanjer and Tammeling, 1983 ) the average TLC of -0.4 standardized residual in the intermediate or high-risk patients means a TLC of 7.02 1 for a 180-cm-tall male adult compared with a predicted value of 7.30 1, which corresponds to a loss of only 4%.
The participants were treated according to several different protocols that, however, represent two basic concepts of childhood ALL therapy: the more simple protocols based on vincrisine, prednisone, I-asparagnase, methotrexate and 6-mercaptopunne, and the more intensive regimens when cranial irradiation, anthracyclines, alkylating agents, epipodophyllotoxins and antimetabolites other than methotrexate or 6-mercaptopurine were added. The five statistically significant multiple regression models for TLC included age at diagnosis and treatment-related risk factors. The latter comprised treatment according to intermediate or highrisk protocols or treatments characteristic of these protocols (doxorubicin, intravenous cyclophosphamide, cytosine arabinoside, cranial irradiation). The treatment-related risk factors were closely interrelated and thus could not be tested against each other. All the models related a lower TLC to cranial irradiation, higher cumulative drug doses and younger age at diagnosis. Our study demonstrates for the first time that therapy for ALL is more lung toxic in young children, a hypodtsis previously put forward (Shaw et al, 1989 However, the body proportions of the participants were normal, and reduced lung function was not related to height It therefore seems more likely that cranial irradiation was significant in our regression models simply because it reflects the more doseintensive reatment protocols.
Age at follow-up was the strongest predictor of TLC in the simple regression models (Table 3 ). This could be explained by a gradual recovery of pulmonary function over decades after the end of chemotherapy. However, there was also a significant correlation between age at follow-up and the doses of the drugs in the multiple regression models. It therefore seems more likely that age at follow-up was significant in a simple regression model because it reflects the change in treatment protocols.
Most participants with reduced transfer coefficient smoked. This, and the fact that the best regression model of transfer factor included only TLC and tobacco smoking, indicates that the reduced transfer factor after chemothrapy seems to be caused mainly by reduced lung volumes. The present data therefore do not suggest thickening of the pulmonary diffusion membrane or reduced pulmonary capillary blood volume.
Methotrexate treatment was related to lung toxicity in some early studies (Clarysse et al, 1969; Nesbit et al, 1976) . In contrast, the more recent studies found no lung toxicity of methotrexate (Miller et al, 1986; Shaw et al, 1989; Jenney et al, 1995 (Shearer et al, 1994 ), but usually after higher doses than those received by our patients. Cytosine arabinoside has not previously been linked to abnormal pulmonary function tests.
Anthracyclines could affect the lung function by inducing congestive heart failure. The cumulative doses of andtracyclines received by our participants, however, were lower than what has yet been reported to cause late clinical cardiotoxicity (Lipshultz et aL 1991; Steinherz et al, 1991) , and only a few patients reported any cardiopulmonary symptoms, which makes this explanation unlikely.
In a large population study the transfer factor was reduced shortly after the onset of smoking, whereas lung volumes were unchanged during the first decade of smoking (Knudson et al, 1989) . Our data were in accordance with this and did not suggest increased pulmonary toxicity of tobacco smoing in survivors of childhood ALL compared with the background population. However, because of the small sample size and the relatively mild tobacco exposure of participants, our study does not have the stanstical power to exclude a clinically relevant increased toxicity of tobacco smoking in those reated with chemothrapy in childood. Tobacco smoking is undoubtedly toxic to the lung, childhood cancer survivors are at increased risk of developing second malignant neoplasms, and many of them have had subclinical damage to several organs causing a reduced functional reserve. Consequently, long-term survivors of childhood cancer should be eagerly warned against tobacco smoking, irrespective of whether the tobacco toxicity to their lungs is actually greater than in the background population or not.
As in a previous study (Jenney et al, 1995) , pulnonary function correlated poorly with self-estimated physical work capacity. Thus, self-esimated physical work capacity can apparently not be used for screening patients for reduced pulnonary function. The prevalence of asthmatic symptoms was lower in our participants than reported in a local population survey study (Backer, 1995) .
Selection bias should not influence our results because patients and controls were selected from population-based cohorts and a high percentage of eligible subjects participated. It is a limitation of our study that the age and height range of participants was wider than that of control subjects. However, our local predictive equations for lung function were generated by adjusting the best available predictive equations from the litrature to fit the large group of local control subjects optimally. The reference equations from the literature that we adjusted are based on subjects covering the full height and age range of our participants. Furthermore, the estimated regression coefficients of our multiple regression models were only minimally affected by limiting the analysis to patients within the height and age range of the control subjects.
The present study was cross-sectional in design and treatment was non-randomly assigned. Consequently, year of diagnosis, length of follow-up, age at follow-up, risk group and type of therapy were all closely related and could therefore not be tested against each other. A cohort effect must be considered as a source of error in a cross-sectional study, but the expected cohort effect would tend to cause the opposite results of what was found. If the drugs given had similar pulonary toxicity, patients teated during the last part of the study period would be expected to have suffered less complications during therapy than patients teated during the first part because of improved supportive care and increasing clinical experience. In contrast with this, patients teated during the last part of the study period acully experienced more puhlonary toxicity.
Studies of late effects are historic in nature: when the long-term toxicity of a treatment protocol is assessable the protocol itself has often been revised several times already, thus necessitating a study of the late effects of the altered prtocol. The recent tendency to increase the dose intensity of treatment protocols for a number of childhood cancers also calls for new studies of late effects. Using a repeated follow-up study of the present cohort, it would be possible to determine whether pulmonary function recovers, stays unchanged or deteriorates late after childhood ALL.
In conclusion, several years after therapy for childhood ALL, participants had a subclinical, slight restrictive pulmonary disease including reduced transfer factor. The reduced pulnonary function was related to young age at tratment and to more dose-intensive protocols. The abnormalities appear mild, but the limited number of patients studied to date, the cross-sectional design of the few available studies and the increased dose intensity of many recent ALL protocols make long-term clinical follow-up of survivors of childhood ALL necessary.
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